Wendy Dicicco

Wendy DiCicco is a veteran healthcare executive with 30 years of financial, operational and corporate development experience. Ms. DiCicco currently serves the emerging growth life sciences community in the role of board member or as financial, executive and board advisory consultant. She currently serves as a consultant for several immuno-oncology and gene therapy companies, including often serving in the role of interim CFO. Ms. DiCicco currently serves on the Boards of Directors of EyePoint Pharmaceuticals (NASDAQ: EYPT), where she serves as the Audit Committee Chair, Carmell Therapeutics, and ExpressCells, life sciences companies in the fields of ophthalmic pharmaceuticals, plasma-based regenerative medicine, and gene editing, respectfully.

She was most recently the Chief Operating and Financial Officer of Centinel Spine, a privately-held designer, developer and worldwide distributor of spinal implants, where she established the Company’s international operations, and was instrumental in both the recapitalization of the Company and in corporate development and global commercialization initiatives. She previously served as President and Chief Operating Officer of Camber Spine Technologies where she significantly expanded the Company’s operations, infrastructure and commercial organization. Prior to Camber Spine, she held several Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Her career started in public accounting at Deloitte & Touche.

Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow and Corporate Governance Fellow of the National Association of Corporate Directors (NACD).